research Dupilumab in the treatment of severe atopic dermatitis refractory to systemic immunosuppression: case report
Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.
Search
for
Sort by
Research
30 / 1000+ results 
research Treatment of chronic alopecia areata with tildrakizumab: an open‐label pilot study
Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
research Successful Treatment of Adalimumab-Induced Paradoxical Skin Reactions in Pustulotic Arthro-Osteitis With Guselkumab
Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.
research Abnormal hair growth in patients (pts) with metastatic colorectal cancer (mCRC) treated with the anti-epidermal growth factor receptor (EGFr) monoclonal antibody (mAb) panitumumab (Pmab)
Panitumumab treatment can cause unusual hair growth in some colorectal cancer patients.
research Alopecia areata after mogamulizumab treatment
Mogamulizumab can cause hair loss and skin rashes.
research Alopecia Areata after Omalizumab Treatment for Chronic Spontaneous Urticaria
Omalizumab may cause hair loss.
research Nemolizumab Treatment for Severe Atopic Dermatitis Led to the Simultaneous Improvement of Coexisting Refractory Alopecia Areata: A Case Report
Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.
research Hypertrichosis, trichomegaly, and androgenic alopecia related to cetuximab treatment
Cetuximab can cause unusual hair growth and hair loss.
research Global Impact of Coronavirus Disease 2019 (COVID-19)
COVID-19 has widely affected health, various industries, and the economy, but also led to more remote work and less pollution.
research Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
Blocking certain proteins can reduce skin inflammation caused by cancer treatment.
research Ixekizumab shows efficacy and safety in patients who failed biweekly etanercept therapy: Analysis From UNCOVER-2, a phase 3 randomized clinical trial in psoriasis
Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.
research Structural behavior of keratin-associated protein 8.1 in human hair as revealed by a monoclonal antibody
KAP8.1 protein is crucial for hair structure and interacts with keratin 85.
research Monoclonal Antibody Against Prolactin Receptor: A Randomized Placebo-Controlled Study Evaluating Safety, Tolerability, and Pharmacokinetics of Repeated Subcutaneous Administrations in Postmenopausal Women
The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
research ANTI-CD19 MONOCLONAL ANTIBODY FOR SYSTEMIC LUPUS ERYTHEMATOSUS AND NEUROMYELITIS OPTICA SPECTRUM DISORDER
Anti-CD19 therapy may help treat SLE and NMOSD.
research 260 Anti-OX40 monoclonal antibody IMG-007 exhibited clinical activity of hair regrowth, suppressed scalp inflammatory biomarkers in patients with severe alopecia areata in a Ph1b/2a study
IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.
research BH14 Multiple sclerosis and alopecia areata: drug-induced alopecia areata or coexisting autoimmune phenomena?
Some multiple sclerosis treatments may trigger hair loss conditions like alopecia areata.
research Evaluation of the Hemogram of Breast Cancer Patients Treated by Therapeutic Protocol Based on Immunohistochemical Analysis: A Retrospective Study
Treatment strategies for breast cancer affect blood health, causing issues like anemia and require nutritional counseling.
research ANIFROLUMAB IN THE MANAGEMENT OF LUPUS HEADACHES: A CASE REPORT
Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.
research Severe steroid-dependent idiopathic angioedema with response to rituximab
A woman with severe angioedema improved significantly after treatment with rituximab.
research Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
Blocking IL-8 can reduce skin rashes from cancer treatment.
research Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib
Dupilumab helped a 4-year-old grow hair back after another treatment failed.
research Data from Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
research Data from Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
research Hypertrichosis of the pinnae in a patient using panitumumab
Panitumumab can cause excessive ear hair growth.
research Severe scarring alopecia associated with combinational use of ficlatuzumab and gefitinib: a clinical and immunohistochemistry study
Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
research Dupilumab and alopecia: A Janus effect
Dupilumab can both heal and cause hair loss.
research Evidence for multiple, developmentally regulated isoforms of Ptprq on hair cells of the inner ear
Ptprq has multiple forms that change during inner ear development.
research BI35 A case of dupilumab-induced scalp psoriasis and review of the literature
Dupilumab can cause psoriasis in some patients.
research BH22 Alopecia areata caused by an adverse reaction to denosumab
Denosumab may cause alopecia areata.
research Challenging Regional Psoriasis and Ustekinumab Biotherapy: Impact of the Patterns of Disease
Ustekinumab might work for severe psoriasis, but more research is needed to be sure.